Argininosuccinic Aciduria
8
1
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Liver Disease in Urea Cycle Disorders
Hepatic Histopathology in Urea Cycle Disorders
Early Check: Expanded Screening in Newborns
Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD
Nitric Oxide Supplementation in Argininosuccinic Aciduria
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder